Please assess the completion status of the following clinical trial:

Trial Title: Low Level Laser Treatment (LLLT) and Lorcaserin for Weight Management

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* be 18-70 years of age;~* have a body weight of greater than 50 kg (110 pounds);~* have a BMI 27-39.9 kg/m2;~* be weight concerned;~* be motivated to reduce their central adiposity;~* be able to participate fully in all aspects of the study;~* have understood and signed study informed consent.~Exclusion Criteria:~* have used weight loss medications or participated in a weight loss program within the past 30 days;~* are currently taking supplements known to affect weight, such as garcinia cambrogia.~* have had weight fluctuations of 20 pounds or more in the past 6 months (self-report);~* have an implanted device (including pacemaker or lap band) in the targeted area of LLLT;~* have an active untreated clinically significant psychiatric condition (psychosis, bipolar disorder, or depression);~* have used an investigational drug within 30 days of study enrollment;~* have a recent history (past 30 days) of alcohol or drug abuse or dependence;~* are currently pregnant or lactating, or are of child-bearing potential or are likely to become pregnant during the medication phase and are unwilling to use a reliable form of contraception;~* have a history of any major cardiovascular events including heart valve disease, cardiac arrhythmias, congestive heart failure, acute coronary syndrome, stroke, transient ischemic attack, or peripheral vascular disease;~* have current uncontrolled hypertension (systolic \> 165 mm Hg or diastolic \> 95 mm Hg) documented on 2 separate occasions;~* have clinically significant acute or chronic progressive or unstable neurologic, hepatic, renal, cardiovascular, lymphatic, respiratory, or metabolic disease (such as diabetes) or active cancer or are within 1 year of cancer remission;~* Prior surgical intervention for body sculpting/weight loss, such as liposuction, abdominoplasty, stomach stapling, lap band surgery, etc.;~* medical, physical, or other contraindications for body sculpting/weight loss;~* current use of medication(s) known to affect weight levels/cause bloating or swelling and for which abstinence during the course of study participation is not safe or medically prudent;~* concurrently taking a serotonergic drug (selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), triptans, bupropion, dextromethorphan, St. John's Wort). These drugs can be used to treat depression and/or migraines but are contraindicated with lorcaserin;~* any medical condition known to affect weight levels and/or to cause bloating or swelling;~* diagnosis of, and/or taking medication for, irritable bowel syndrome;~* active infection, wound or other external trauma to the areas to be treated with the laser;~* known photosensitivity disorder;~* are allergic to lorcaserin;~* current active cancer or currently receiving treatment for cancer; or~* have a known history of any condition or factor judged by the investigator to preclude participation in the study or which might hinder adherence;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- LLLT (Type: ACTIVE_COMPARATOR): Low Level Laser Therapy (LLLT) once a week for 12 weeks
- Lorcaserin (Type: ACTIVE_COMPARATOR): locarserin monotherapy - 10 mg, twice daily for 12 weeks
- LLLT and Lorcaserin (Type: ACTIVE_COMPARATOR): LLLT once a week for 12 weeks and 10 mg of Lorcaserin twice daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).